

Performance in Delivering Clinical Research - Quarter 1 (2017/18)

Note: Chelsea and Westminster Hospital NHS Foundation Trust formally acquired West Middlesex University Hospital NHS Trust on 01 September 2015, and the submission for the former West Middlesex University Hospital NHS Trust has been subsumed into this submission

All hosted, commercial clinical trials closed to recruitment between 01 July 2016 – 31 June 2017

Research Ethics Committee Reference Number	Name of Trial	Target	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
14/LO/2196	A phase 2, double-blind, parallel group, randomised, placebo controlled, proof of concept study to assess the safety and efficacy of OBE001 after oral administration in pregnant women with threatened preterm labour.	1	25/07/2016	0	Withdrawn By Sponsor	Sponsor terminated the study early with only 10 patients recruited globally out of 100
14/LO/0565	A Multicentre, Randomised, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Lubiprostone in Paediatric Subjects Aged = 6 Years to < 18 Years with Functional Constipation	2	06/09/2016	3	Recruitment Finished	Over recruited by 1 patients
14/LO/0816	A Multicentre, Long-term Safety, Efficacy, and Pharmacokinetics Study of Lubiprostone in Paediatric Subjects Aged 6 Years to less than 18 Years with Functional Constipation	0	01/07/2016	1	Recruitment Finished	This study was an extension to IRAS 145189 and only patients completing the main study could be approached to enter this study. Out of the 3 that completed the main study just one opted

						to join the extension study.
16/LO/0240	An open-label, prospective, non-randomized, multicenter study to evaluate clear skin effect on health-related quality of life outcomes at 16 and 52 weeks in patients with moderate to severe plaque psoriasis treated with secukinumab 300 mg s.c. with or without	5	26/04/2017	2	Recruitment Finished	Study was a global study with competitive recruitment. Global target was hit before we managed to recruit our local target.
16/EE/0223	A 24-week, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of Toujeo? and Tresiba? in Insulin-Naive Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Oral Antihyperglycemic Drug(s)	4	28/04/2017	0	Withdrawn By Sponsor	Study difficult to recruit too nationally. The changing therapy landscape in type 2 diabetes have pushed insulins further down the pathway hence the paucity of suitable numbers. Sponsor chose to close the study to recruitment nationally. No patients recruited locally.